These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 30520145)

  • 121. Fecal microbiota transplantation with ruxolitinib as a treatment modality for steroid-refractory/dependent acute, gastrointestinal graft-versus-host disease: A case series.
    Biliński J; Jasiński M; Tomaszewska A; Lis K; Kacprzyk P; Chmielewska L; Karakulska-Prystupiuk E; Mullish BH; Basak GW
    Am J Hematol; 2021 Dec; 96(12):E461-E463. PubMed ID: 34587331
    [No Abstract]   [Full Text] [Related]  

  • 122. Topical Ruxolitinib for the Treatment of Alopecia Universalis.
    Craiglow BG; Tavares D; King BA
    JAMA Dermatol; 2016 Apr; 152(4):490-1. PubMed ID: 26649829
    [No Abstract]   [Full Text] [Related]  

  • 123. Tofacitinib for polyarteritis nodosa: a tailored therapy.
    Rimar D; Alpert A; Starosvetsky E; Rosner I; Slobodin G; Rozenbaum M; Kaly L; Boulman N; Awisat A; Ginsberg S; Zilber K; Shen-Orr SS
    Ann Rheum Dis; 2016 Dec; 75(12):2214-2216. PubMed ID: 27558986
    [No Abstract]   [Full Text] [Related]  

  • 124. Response to Moreno-Vílchez et al., "Baricitinib for the treatment of alopecia areata in adults: Real world analysis of 36 patients".
    Desai D; Nohria A; Shapiro J; Lo Sicco K
    J Am Acad Dermatol; 2024 Aug; 91(2):e39-e40. PubMed ID: 38631444
    [No Abstract]   [Full Text] [Related]  

  • 125. Alopecia areata flare patterns in children and young adults while on systemic tofacitinib.
    McKenzie PL; Castelo-Soccio L
    J Am Acad Dermatol; 2022 Mar; 86(3):683-685. PubMed ID: 33667538
    [No Abstract]   [Full Text] [Related]  

  • 126. Tofacitinib for the Treatment of Trachyonychia.
    Zhong X; Liu T; Wei L; Bai J; Fang H; Qiao J
    Am J Ther; 2024 Jul-Aug 01; 31(4):e468-e470. PubMed ID: 38976532
    [No Abstract]   [Full Text] [Related]  

  • 127. How suitable are JAK inhibitors in treating the inflammatory component in patients with alopecia areata and vitiligo?
    Moya EC; Bruinsma RL; Kelly KA; Feldman SR
    Expert Rev Clin Immunol; 2022 Mar; 18(3):189-191. PubMed ID: 35107044
    [No Abstract]   [Full Text] [Related]  

  • 128. Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic.
    Aşkın Ö; Özkoca D; Uzunçakmak TK; Serdaroğlu S
    Dermatol Ther; 2021 Mar; 34(2):e14746. PubMed ID: 33405372
    [TBL] [Abstract][Full Text] [Related]  

  • 129. Treatment of dermatomyositis with ruxolitinib.
    Fioranelli M; Roccia MG; Lotti T
    Dermatol Ther; 2016 Jul; 29(4):285. PubMed ID: 26448614
    [No Abstract]   [Full Text] [Related]  

  • 130. Tofacitinib: a successful treatment option for SAPHO syndrome.
    Sarikaya Solak S; Yelgen Ilyas H
    Int J Dermatol; 2024 May; 63(5):671-674. PubMed ID: 38357788
    [No Abstract]   [Full Text] [Related]  

  • 131. Extramedullary haematopoiesis within hepatic sinusoids of a patient with primary myelofibrosis.
    Yamazaki K; Suzuki S; Kawaguchi T
    Br J Haematol; 2022 Mar; 196(5):1130. PubMed ID: 34796484
    [No Abstract]   [Full Text] [Related]  

  • 132. Successful treatment of chronic severe alopecia areata with abrocitinib.
    Bennett M; Moussa A; Sinclair R
    Australas J Dermatol; 2022 May; 63(2):274-276. PubMed ID: 35390171
    [No Abstract]   [Full Text] [Related]  

  • 133. Topical Janus kinase-signal transducers and activators of transcription inhibitor tofacitinib is effective in reducing nonatopic dermatitis chronic itch: A case series.
    Ju T; Labib A; Vander Does A; Yosipovitch G
    J Am Acad Dermatol; 2022 Aug; 87(2):400-403. PubMed ID: 35278487
    [No Abstract]   [Full Text] [Related]  

  • 134. Tofacitinib for severe alopecia areata: experience from a university tertiary hospital.
    Amoedo P; Matos PR; Mota A; Pedrosa AF
    Eur J Dermatol; 2024 Feb; 34(1):100-102. PubMed ID: 38557471
    [No Abstract]   [Full Text] [Related]  

  • 135. Challenges of securing insurance approval for oral tofacitinib for the treatment of alopecia areata: a multi-institution retrospective review.
    Desai S; Lo K; Nambudiri VE; Villa-Ruiz C; LaChance A; Vleugels RA
    Arch Dermatol Res; 2022 Jul; 314(5):487-489. PubMed ID: 33403573
    [TBL] [Abstract][Full Text] [Related]  

  • 136. Journal club: JAK inhibitors and safety.
    Diaz AR; Dege T; Chircop I; Reynaud V; Byrne N; Lé A; Garcia-Piqueras P
    Eur J Dermatol; 2024 Jun; 34(3):338-340. PubMed ID: 39015988
    [No Abstract]   [Full Text] [Related]  

  • 137. New developing multiple sclerosis in a patient using tofacitinib due to alopesia areata.
    Erçoban R; İslamoğlu ZGK
    Dermatol Ther; 2022 Jun; 35(6):e15477. PubMed ID: 35355384
    [No Abstract]   [Full Text] [Related]  

  • 138. Management of Alopecia Areata With Topical JAK Inhibitor Therapy: An Evidence-Based Review.
    Abduelmula A; Mufti A; Mistry J; Sachdeva M; Beecker J; Prajapati VH; Yeung J
    J Cutan Med Surg; 2023; 27(1):73-75. PubMed ID: 36189927
    [No Abstract]   [Full Text] [Related]  

  • 139. The status and outcomes of registered clinical trials for Janus kinase inhibitors in alopecia areata: are unpublished trials being overlooked?
    Steele L; Lee HL; Maruthappu T; O'Toole EA
    Clin Exp Dermatol; 2021 Oct; 46(7):1290-1292. PubMed ID: 33608909
    [TBL] [Abstract][Full Text] [Related]  

  • 140. A retrospective study of oral tofacitinib therapy for alopecia areata.
    Lima XTV; Bambery M; Alora MB
    An Bras Dermatol; 2023; 98(2):221-224. PubMed ID: 36682967
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.